AZAndrea Zitella

Andrea Zitella

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrea Zitella has a total of 135 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figure from Association Study between Polymorphisms in DNA Methylation–Related Genes and Testicular Germ Cell Tumor Risk

    by Chiara Grasso, Maja Popovic, Elena Isaevska, Fulvio Lazzarato, Valentina Fiano, Daniela Zugna, John Pluta, Benita Weathers, Kurt D'ANdrea, Kristian Almstrup, et al.

    Supplementary Figure from Association Study between Polymorphisms in DNA Methylation–Related Genes and Testicular Germ Cell Tumor Risk

  • Open Access

    Supplementary Data from Association Study between Polymorphisms in DNA Methylation–Related Genes and Testicular Germ Cell Tumor Risk

    by Chiara Grasso, Maja Popovic, Elena Isaevska, Fulvio Lazzarato, Valentina Fiano, Daniela Zugna, John Pluta, Benita Weathers, Kurt D'ANdrea, Kristian Almstrup, et al.

    Supplementary Data from Association Study between Polymorphisms in DNA Methylation–Related Genes and Testicular Germ Cell Tumor Risk

  • Open Access

    Quality of life in low-risk prostate cancer under active surveillance or following radical treatments: the START cohort study

    by Rosalba Rosato, Stefano De Luca, Andrea Zitella, Fernando Munoz, Carlo Giuliano Baima, Maurizio Barale, Franco Bardari, Debora Beldì, Luca Bellei, Andrea Rocco Bellissimo, et al.

    Background Real-world evidence on quality of life (QoL) changes associated with treatment decisions is crucial for informed choices by patients with low-risk prostate cancer (LRPC). Methods A prospective cohort study was conducted in the Piemonte and Valle d’Aosta Regional Oncology Network, NW Italy (4.5 million population), including nearly all urology (N = 22) and radiation oncology (N = 6) centres. Patients newly diagnosed with LRPC, eligible for radical treatments, received balanced information on risks and benefits of available options and could choose among active surveillance (AS), radical prostatectomy (RP), or radiotherapy (RT). Longitudinal changes in QoL were assessed via patient-reported outcomes in four domains: general QoL, mental health, sexual function and urinary/bowel symptoms. The main comparison was between AS and RP. A secondary comparison was between AS and all radical treatments (RP or RT). Data were analysed by multivariable generalised linear or logistic models, following the intention-to-treat principle and accounting for correlation within centres and subjects. Results A total of 651 patients (76.4% of those enrolled, 559 in AS, 76 in RP and 16 in RT) with baseline questionnaires were included (median [IQR] age, 70 [64–74] years). During a median follow-up of 37 months, no differences in general QoL or mental health were observed between AS and RP. Men in AS had better scores for sexual function (β = 8.27, 95% CI: 5.57–10.96) and activity (β = 6.70, 95% CI: 4.19–9.20). Use of incontinence aids was significantly lower in the AS group (OR = 0.14; 95% CI: 0.09–0.23). Prostatic obstructive symptoms remained stable in AS but decreased in the RP group (OR = 2.77; 95% CI: 1.52–5.06). Results were similar comparing AS to RP or RT. Conclusions Compared to radical prostatectomy, AS preserved urinary continence and sexual function but was associated with persistent obstructive symptoms, without differences in general QoL or mental health. This real-world study supports existing evidence, aiding LRPC patients in making informed decisions.


  • Open Access

    Integrating anamnestic and lifestyle data with sphingolipid levels for risk-based prostate cancer screening

    by Caterina Peraldo-Neia, Paola Ostano, Melissa Savioli, Maurizia Mello-Grand, Ilaria Gregnanin, Francesca Guana, Francesca Crivelli, Francesco Montagnani, Michele Dei-Cas, Rita Paroni, et al.

    Background: In the era of risk-based prostate cancer (PCa) screening, overcoming the limitations of prostate-specific antigen (PSA) testing and stratifying men by individual risk is crucial. Our study aims to integrate anamnestic and lifestyle data with circulating biomarkers to minimize unnecessary second-level investigations (SLIs) for patients with suspected PCa, while improving the detection of clinically significant PCa (ISUP > 1). Methods: We collected plasma samples, recent clinical history, family cancer history, PSA levels, and lifestyle information from 904 men: 421 undergoing PSA testing, 421 with suspected and 62 with confirmed PCa. Univariable logistic regression was applied to identify ananmestic and lifestyle variables mostly associated with PCa. Penalized logistic regression models predictive of PCa or ISUP > 1 PCa were built both using the 814 subjects with complete information for such variables, applying a 10-fold cross validation approach, and dividing the dataset into a training (n = 445: 132 PCa, 313 non-PCa) and a test (n = 369: 147 PCa, 222 non-PCa) set. The concentration of 50 sphingolipids was analysed on the latter set of 369 subjects by mass-spectrometry, and multivariable penalized regression with 10-fold cross-validation was applied to integrate anamnestic, lifestyle, sphingolipid data. ROC-AUCs on the test sets were compared with PSA ROC-AUCs. Results: Age, cardiovascular disease (CVD), number of medications, and sedentariness were significantly associated with PCa detection and their combination with PSA improved its performance (ROC-AUC from 0.85 to 0.89). In the SLI subgroup (n = 437), adding age improved PSA predictive power (ROC-AUC from 0.60 to 0.70), but performance was still poor. Penalized regression with 10-fold cross-validation on the sphingolipid dataset identified hypertension, CVD, PSA, age, and five sphingolipids (HexCer-20, Cer-20, HexCer-24.1, GM3-24.1, DHCer-24) as key variables for accurate PCa classification (average ROC-AUC: 0.92). Cer-20 and CVD were consistently selected by models predicting ISUP > 1 PCa. In the SLI subgroup, PSA, age, CVD, SM-16, HexCer-20, HexCer-24.1, DHS1P, and DHCer-24 were selected in all 10 models (average ROC-AUC: 0.83). Conclusions: Circulating sphingolipids are promising biomarkers that, when combined with PSA, anamnestic, and lifestyle data, may enhance PCa screening precision and reduce the need for invasive, costly examinations.


  • Open Access

    Integrating anamnestic and lifestyle data with sphingolipid levels for risk-based prostate cancer screening

    by Caterina Peraldo-Neia, Paola Ostano, Melissa Savioli, Maurizia Mello-Grand, Ilaria Gregnanin, Francesca Guana, Francesca Crivelli, Francesco Montagnani, Michele Dei-Cas, Rita Paroni, et al.

    Background: In the era of risk-based prostate cancer (PCa) screening, overcoming the limitations of prostate-specific antigen (PSA) testing and stratifying men by individual risk is crucial. Our study aims to integrate anamnestic and lifestyle data with circulating biomarkers to minimize unnecessary second-level investigations (SLIs) for patients with suspected PCa, while improving the detection of clinically significant PCa (ISUP>1). Methods: We collected plasma samples, recent clinical history, family cancer history, PSA levels, and lifestyle information from 904 men: 421 undergoing PSA testing, 421 with suspected and 62 with confirmed PCa. Univariable logistic regression was applied to identify ananmestic and lifestyle variables mostly associated with PCa. Penalized logistic regression models predictive of PCa or ISUP>1 PCa were built both using the 814 subjects with complete information for such variables, applying a 10-fold cross validation approach, and dividing the dataset into a training (n=445: 132 PCa, 313 non-PCa) and a test (n=369: 147 PCa, 222 non-PCa) set. The concentration of 50 sphingolipids was analysed on the latter set of 369 subjects by mass-spectrometry, and multivariable penalized regression with 10-fold cross-validation was applied to integrate anamnestic, lifestyle, sphingolipid data. ROC-AUCs on the test sets were compared with PSA ROC-AUCs. Results: Age, cardiovascular disease (CVD), number of medications, and sedentariness were significantly associated with PCa detection and their combination with PSA improved its performance (ROC-AUC from 0.85 to 0.89). In the SLI subgroup (n=437), adding age improved PSA predictive power (ROC-AUC from 0.60 to 0.70), but performance was still poor. Penalized regression with 10-fold cross-validation on the sphingolipid dataset identified hypertension, CVD, PSA, age, and five sphingolipids (HexCer-20, Cer-20, HexCer-24.1, GM3-24.1, DHCer-24) as key variables for accurate PCa classification (average ROC-AUC: 0.92). Cer-20 and CVD were consistently selected by models predicting ISUP>1 PCa. In the SLI subgroup, PSA, age, CVD, SM-16, HexCer-20, HexCer-24.1, DHS1P, and DHCer-24 were selected in all 10 models (average ROC-AUC: 0.83). Conclusions: Circulating sphingolipids are promising biomarkers that, when combined with PSA, anamnestic, and lifestyle data, may enhance PCa screening precision and reduce the need for invasive, costly examinations.

  • Association Study between Polymorphisms in DNA Methylation–Related Genes and Testicular Germ Cell Tumor Risk

    by Chiara Grasso, Maja Popovic, Elena Isaevska, Fulvio Lazzarato, Valentina Fiano, Daniela Zugna, John Pluta, Benita Weathers, Kurt D'ANdrea, Kristian Almstrup, et al.

    Background: Testicular germ cell tumors (TGCT), histologically classified as seminomas and nonseminomas, are believed to arise from primordial gonocytes, with the maturation process blocked when they are subjected to DNA methylation reprogramming. SNPs in DNA methylation machinery and folate-dependent one-carbon metabolism genes have been postulated to influence the proper establishment of DNA methylation. Methods: In this pathway-focused investigation, we evaluated the association between 273 selected tag SNPs from 28 DNA methylation–related genes and TGCT risk. We carried out association analysis at individual SNP and gene-based level using summary statistics from the Genome Wide Association Study meta-analysis recently conducted by the international Testicular Cancer Consortium on 10,156 TGCT cases and 179,683 controls. Results: In individual SNP analyses, seven SNPs, four mapping within MTHFR, were associated with TGCT risk after correction for multiple testing (q ≤ 0.05). Queries of public databases showed that three of these SNPs were associated with MTHFR changes in enzymatic activity (rs1801133) or expression level in testis tissue (rs12121543, rs1476413). Gene-based analyses revealed MTHFR (q = 8.4 × 10–4), methyl-CpG–binding protein 2 (MECP2; q = 2 × 10–3), and ZBTB4 (q = 0.03) as the top TGCT-associated genes. Stratifying by tumor histology, four MTHFR SNPs were associated with seminoma. In gene-based analysis MTHFR was associated with risk of seminoma (q = 2.8 × 10–4), but not with nonseminomatous tumors (q = 0.22). Conclusions: Genetic variants within MTHFR, potentially having an impact on the DNA methylation pattern, are associated with TGCT risk. Impact: This finding suggests that TGCT pathogenesis could be associated with the folate cycle status, and this relation could be partly due to hereditary factors.


  • Feasibility and complications of in-office transperineal free-hand prostate biopsies under local anesthesia: A single center prospective study

    by A. Marquis, G. Marra, M. Oderda, S. Tappero, D. D’agate, G. Calleris, A. Zitella, A. Greco, M. Falcone, A. Bisconti, et al.